Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.36 |
| ▸ | JAK3 | P52333 | 4/20 | 0.36 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29968129 | 0.90 | JAK2 (0.43) | ALDH1A1MAPK1HTTOPRK1JAK3 | |
| SCHEMBL26130781 | 0.90 | JAK2 (0.43) | ALDH1A1MAPK1HTTOPRK1JAK3 | |
| SCHEMBL26127971 | 0.88 | ALDH1A1 (0.40) | ALDH1A1MAPK1HTTOPRK1JAK3 | |
| SCHEMBL29969671 | 0.88 | ALDH1A1 (0.40) | ALDH1A1MAPK1HTTOPRK1JAK3 | |
| SCHEMBL29493167 | 0.87 | ALDH1A1 (0.47) | ALDH1A1MAPK1HTTOPRK1JAK3 | |
| SCHEMBL26130393 | 0.87 | ALDH1A1 (0.47) | ALDH1A1MAPK1HTTOPRK1JAK3 | |
| SCHEMBL26130281 | 0.87 | ALDH1A1 (0.39) | ALDH1A1MAPK1HTTOPRK1JAK3 | |
| SCHEMBL29969938 | 0.84 | ALDH1A1 (0.40) | ALDH1A1MAPK1HTTOPRK1JAK3 | |
| SCHEMBL26131044 | 0.84 | ALDH1A1 (0.40) | ALDH1A1MAPK1HTTOPRK1JAK3 | |
| SCHEMBL29968653 | 0.83 | ALDH1A1 (0.36) | ALDH1A1MAPK1HTTOPRK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119684291-A | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | 艾科思莱德制药公司 | 2025-03-25 | — | — | CN | disclosed |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| CN-114258301-B | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | 艾科思莱德制药公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-4288423-A1 | COMBINATION OF DUAL ATM AND DNA-PK INHIBITORS AND IMMUNOTHERAPEUTIC AGENTS FOR USE IN CANCER THERAPY | XRad Therapeutics, Inc. (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-117015534-A | Combination of dual ATM and DNA-PK inhibitors for cancer therapy and immunotherapeutic agents | 艾科思莱德制药公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
| WO-2022169840-A1 | COMBINATION OF DUAL ATM AND DNA-PK INHIBITORS AND IMMUNOTHERAPEUTIC AGENTS FOR USE IN CANCER THERAPY | XRAD THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | WO | disclosed |
| EP-4003345-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20220142995-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-05-12 | — | — | US | disclosed |
| CN-114258301-A | Dual ATM and DNA-PK inhibitors for use in antitumor therapy | 艾科思莱德制药公司 | 2022-03-29 | — | — | CN | disclosed |
| WO-2021022078-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | ALDH1A1 3354/4885MAPK1 1184/4885HTT 2506/4885 |
| US-20220142995-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | ALDH1A1 3154/4885MAPK1 963/4885HTT 2365/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | ALDH1A1 3354/4885MAPK1 1184/4885HTT 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.